Form 4 for ABOS Acumen Pharmaceuticals, Inc.
Accepted 2025-01-07 00:00:00 ET · period of report 2025-01-03 · accession 0001576885-25-000015 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-07 | 2025-01-06 | ABOS | Meisner Derek M | CLO, Corp Sec | A - Grant | $0.00 | +66.8K | 164.5K | +68% | $0 |
| D | 2025-01-07 | 2025-01-03 | ABOS | Meisner Derek M | CLO, Corp Sec | S - Sale | $1.84 | -11.1K | 97.7K | -10% | -$20.5K |
| D | 2025-01-07 | 2025-01-06 | ABOS | Meisner Derek M | CLO, Corp Sec | A - Grant | $0.00 | +100.3K | 100.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-06 | A | A | 66,800 | $0.00 | 164,545 | D | — | — | (F3) Represents an RSU award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. |
| 2 | Common | Common Stock | 2025-01-03 | S | D | 11,122 | $1.84 | 97,745 | D | — | — | (F1) Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2024. (F2) The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7750 to $1.9300. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Derivative | Employee Stock Option (right to buy) | 2025-01-06 | A | A | 100,300 | $0.00 | 100,300 | D | $1.85 · — to 2035-01-06 | 100,300 Common Stock | (F4) The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. |